Karyopharm Therapeutics

KPTI

Market cap $93.1M

NEWTON, Mass. , Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted a stock option to purchase an aggregate of 2,800 shares of Karyopharm's common stock and an  aggregate of 15,791 restricted stock units (RSUs) to seven newly-hired employees.

NEWTON, Mass. , Dec. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company's senior management team will participate at the Piper Sandler 37th Annual Healthcare Conference in a fireside chat on Thursday, December 4, 2025 at 10:30 a.m.

NEWTON, Mass. , Nov. 3, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 800 restricted stock units (RSUs) to one newly-hired employee.

Karyopharm Therapeutics Inc. ( KPTI ) Q3 2025 Earnings Call November 3, 2025 8:00 AM EST Company Participants Brendan Strong - SVP of Investor Relations & Corporate Communications Richard Paulson - President, CEO & Director Reshma Rangwala - Executive VP, Chief Medical Officer & Head of Research Sohanya Cheng - Executive VP, Chief Commercial Officer & Head of Business Development Lori Macomber - EVP, CFO & Treasurer Conference Call Participants Peter Lawson - Barclays Bank PLC, Research Division Edward Tenthoff - Piper Sandler & Co., Research Division Colleen Hanley - Robert W. Baird & Co. Incorporated, Research Division Maurice Raycroft - Jefferies LLC, Research Division Brian Abrahams - RBC Capital Markets, Research Division Jonathan Chang - Leerink Partners LLC, Research Division Presentation Operator Good morning.

– Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – – Total Revenue was $44.0 Million; U.S. XPOVIO® (selinexor) Net Product Revenue was $32.0 Million, an increase of 8.5% compared to Third Quarter of 2024 – – Reaffirms Full-Year 2025 Total Revenue Guidance of $140 Million to $155 Million and U.S. XPOVIO Net Product Revenue Guidance of $110 Million to $120 Million – –  Conference Call Scheduled for Today at 8:00 a.m. ET – NEWTON, Mass.

-- Conference Call Scheduled for Monday, November 3, 2025, at 8:00 a.m. ET -- NEWTON, Mass.

Karyopharm Therapeutics Inc. (KPTI) is looking like an interesting pick from a technical perspective, as the company reached a key level of support. Recently, KPTI's 50-day simple moving average crossed above its 200-day simple moving average, known as a "golden cross.

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) on Wednesday announced comprehensive financing and capital structure transactions expected to provide the company with  $100 million of financial flexibility and additional capital, extending the cash runway into the second quarter of 2026.

– Transactions Provide Karyopharm with $100 Million of Financial Flexibility and Additional Capital – – Preliminary Total Revenue and U.S. XPOVIO® (selinexor) Net Product Revenue for the Third Quarter of 2025 Expected to be in the Range of $42 to $44 Million and Approximately $32 Million, Respectively – – Top-Line Data from the Phase 3 SENTRY Trial in Myelofibrosis on Track for March 2026 – NEWTON, Mass. , Oct. 8, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that it has entered into  comprehensive financing and capital structure transactions expected to provide the Company with  $100 million of financial flexibility and additional capital, extending the Company's cash runway into the second quarter of 2026 based on the Company's current operating plans.

NEWTON, Mass. , Oct. 1, 2025 /PRNewswire/ -- Karyopharm Therapeutics Inc. (Nasdaq: KPTI), a commercial-stage pharmaceutical company pioneering novel cancer therapies, today announced that the Company granted an aggregate of 333 restricted stock units (RSUs) to one newly-hired employee.